AFT PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.8 NZD | -3.45% |
|
-6.67% | -20.00% |
| May. 01 | AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV | MT |
| Apr. 24 | New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment | MT |
Presenter SpeechDavid Flacks (Executives)Okay. [Foreign Language] Good morning, and welcome to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.8
NZD
Average target price
3.7
NZD
Spread / Average Target
+32.14%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 177M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- AFT Stock
- News AFT Pharmaceuticals Limited
- Transcript : AFT Pharmaceuticals Limited - Shareholder/Analyst Call